Navigation Links
Lexicon Pharmaceuticals to Present at the 29th Annual JPMorgan Healthcare Conference
Date:1/4/2011

THE WOODLANDS, Texas, Jan. 4, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the JPMorgan Healthcare Conference in San Francisco, California on Monday, January 10, 2011 at 10:30 a.m. Pacific Time.  Dr. Sands will provide an overview of Lexicon's latest clinical data and drug development objectives.

A live webcast of the presentation will be available through Lexicon's corporate website at www.lexpharma.com. An archived version of the presentation will be available for 30 days after the event.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
2. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results
3. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
4. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2010 Financial Results
5. Lexicon Pharmaceuticals Announces Reacquisition of All Rights to Symphony Icon Programs
6. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
7. Lexicon Presents Positive Outcome in IBS Patients Treated With LX1031 and Data Supporting Mechanism of Action
8. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
9. Lexicon to Present at BIO International Convention
10. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
11. Lexicon Announces Proposed $95 Million Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017 Summary Provides ... partnering deals and agreements entered into by the worlds ... http://www.reportlinker.com/p03605668-summary/view-report.html Description The Global Non-Small Cell Lung ... understanding and access to partnering deals and agreements entered ... - Trends in partnering deals - Top deals ...
(Date:2/22/2017)... , February 22, 2017 Arthroscopy Devices Market Report, published ... in 2015 and is projected to reach $5,334 million by 2022, growing at a ... of the total market in 2015. Continue Reading ... ... ...
(Date:2/22/2017)... MERIDEN, Conn. , Feb. 22, 2017   ... and maker of Flublok® Influenza Vaccine , announced ... The Partnership for Influenza Vaccine Introduction (PIVI) and the ... the devastating impacts of the flu.  The doses of ... of Mongolia for health care ...
Breaking Medicine Technology:
(Date:2/22/2017)... IL (PRWEB) , ... February 22, 2017 , ... South ... is proud to once again feature Heroes On The Water (HOW), a non-profit organization ... season’s all new episode has series host ‘Mike D’ traveling to Lake Denmark, New ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... chronic conditions reported skipping doses or not filling a prescription because they could ... rates of cost-related problems getting medications were 30-60%*. At the same ...
(Date:2/22/2017)... ... 2017 , ... Sideline Products participated in the World Horse Expo held in ... and his production crew. Tom Seay’s program “Best of America by Horseback” is ... Sidekicks will be featured on April 6, 2017. After the broadcast, the clip will ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... country today, as organizations, advocates, and individuals join together to increase recognition about ... to ultimately save lives. , “Today we mark a nationwide movement to raise ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s ... spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon ... small number of neurosurgeons in Michigan performing minimally invasive back surgery that often ...
Breaking Medicine News(10 mins):